BioNxt Solutions Inc.
VANCOUVER, BC / ACCESSWIRE / July 9, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report that it has signed a master services agreement ("MSA") with a German-based international contract research, development, and manufacturing organization (the "CRDMO"). The MSA will serve as the foundation for BioNxt's future product development, particularly its pipeline of oral dissolvable ("ODF") drug formulations.
With a head office in Munich, Germany, the CRDMO is an international network of pharmaceutical service providers with facilities in five countries and over 500 employees. They offer GCP/GLP/GMP/ISO/IEC-certified services and GMP certified manufacturing of clinical trial supplies (Phase I-III) with a specialization in solids, semi-solids, liquids, oral films, and transdermal patches. The CRDMO also offers integrated lab analytical services during development & GMP manufacturing, including API characterization, method development, optimization, validation, permeation studies, stabilities studies, etc.
"This is a very important step for our company," stated Wolfgang Probst, Interim CEO and Director of BioNxt. "With the recent success of our Cladribine ODF toxicity and comparative PK study, we are eager to advance the program to the next stage, namely the human comparative bioequivalence study. The MSA we just signed puts BioNxt in a position to satisfy all the necessary laboratory, technical, and regulatory steps toward clinical studies and product commercialization."
BioNxt is developing a 100% owned and proprietary ODF Cladribine dosage form, directed at the multiple sclerosis ("MS") market. Cladribine tablets are currently approved for use in over 75 countries, including by the United States Food and Drug Administration ("FDA") and the European Medicines Agency ("EMA"), with annual sales in excess of one billion USD. Cladribine tablets are approved for several indications, namely highly active forms of relapsing-remitting MS and certain forms of leukemia. MS represents the largest market segment for the sale of Cladribine with approximately 2.3 million people living with MS worldwide, with the highest prevalence in North America and Europe, noted by Atlas of MS. The global Multiple Sclerosis drug market is expected to top USD 41 billion by 2033 according to Market.us.
The Company has filed Cladribine ODF-related provisional patent applications with three to four patent applications expected to be on file in major international jurisdictions by late 2024 to early 2025 with potential patent protection extending to 2044.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience accelerator focused on next-generation drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical production and evaluation, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization and clinical evaluation of emerging active pharmaceutical ingredients for neurological applications. The Company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.
BioNxt Solutions Inc.
Wolfgang Probst, CEO and Director
Email: info@bionxt.com
Phone: +1 780-818-6422
Cautionary Statement Regarding "Forward-Looking" Information
Some of the statements contained in this news release are forward-looking statements and information within the meaning of applicable securities laws. Forward-looking statements and information can be identified by the use of words such as "expects", "intends", "is expected", "potential", "suggests" or variations of such words or phrases, or statements that certain actions, events or results "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements and information are not historical facts and are subject to a number of risks and uncertainties beyond the Company's control. Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this news release. Accordingly, readers should not place undue reliance on forward-looking statements. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements, except as may be required by law.
SOURCE: BioNxt Solutions Inc.
View the original press release on accesswire.com
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Medical Components Specialists to Exhibit at Medical Technology Ireland 202519.9.2025 16:00:00 CEST | Press release
BELLINGHAM, MASSACHUSETTS / ACCESS Newswire / September 19, 2025 / Medical Components Specialists (MCS), a leading contract manufacturer of precision medical devices, announced its participation in the upcoming Medical Technology Ireland Expo and Conference, taking place September 24-25 at the Galway Racecourse. Medical Technology Ireland has become Europe's second-largest and fastest-growing medical device design event. This year, the conference is expected to draw more than 2,000 attendees and over 350 exhibitors, showcasing the latest innovations and solutions driving the Irish medtech sector. Over the course of two days, the conference program will feature sessions on topics including the future of Irish MedTech, unlocking global opportunities through innovation, the Women in MedTech Forum, and advancements in catheter technologies, among others. The event provides a platform for knowledge exchange, networking, and exploration of cutting-edge medical technologies shaping the global
Theometrics Global Partners With Acclaimed Designer Cristina Zavati to Launch 'MeaDea by Theo,' Championing Resilience at New York Fashion Week19.9.2025 15:00:00 CEST | Press release
NEW YORK CITY, NEW YORK / ACCESS Newswire / September 19, 2025 / Theometrics Global is proud to announce a new partnership with celebrated designer and founder of the renowned IELLELE brand, Cristina Zavati, to launch an exclusive new collection, "MeaDea by Theo." This collaboration, is a significant step in Theometrics' global mission to empower young creators, and will be officially unveiled during New York Fashion Week.'Magna Graecia Resurrected - Divine Femininity and Hellenic Design in Analipsi' Captured in Analipsi, Greece - an Ensemble of Crowned Beauty, Visionary Creators and Fashion Rooted in Ancient Legacy "As the world sees the glamour of Fashion Week on the world's biggest stage, let us recognize the blood, sweat, and tears that designers and models have to overcome," said Sotirios Hristos Stathopoulos (aka Sam Stathis). September is Suicide Awareness Month and Theometrics Global has consistently raised awareness for this cause, as it did in the 2023 fashion weeks in New Yo
Ondas Appoints Technologist and British Army Veteran Karl Eze as UK Strategic Advisor to Ondas Capital19.9.2025 14:40:00 CEST | Press release
Appointment strengthens Ondas Capital's presence in the United Kingdom to support technology and defense development initiatives Seasoned executive brings military, financial, and entrepreneurial experience to accelerate Ondas Capital's international strategy LONDON, UK / ACCESS Newswire / September 19, 2025 / Ondas Holdings Inc. (NASDAQ:ONDS) ("Ondas" or the "Company"), a leading provider of autonomous aerial and ground robot intelligence and private wireless solutions through its business units Ondas Autonomous Systems (OAS) and Ondas Networks, today announced that Karl Eze has been appointed as Strategic Advisor for the United Kingdom for Ondas Capital. Based in London, Mr. Eze will represent Ondas Capital, providing strategic insight into technology and defense markets, strengthening industry relationships, and supporting Ondas' mission to connect advanced technology, defense innovation, and global opportunities. "Ondas Capital is building a strong international platform," said Jam
Air Quality Solutions Launches the UK's Most Advanced Software for Air Quality Assessments19.9.2025 08:00:00 CEST | Press release
New cloud-based app helps Air Quality Consultants deliver Air Quality Assessments for planning applications 80% faster. NOTTINGHAM, UK / ACCESS Newswire / September 19, 2025 / Air Quality Solutions announces the launch of its ground-breaking Air Quality Software. This game-changing app enables air quality consultants to reliably complete assessments 80% faster and with higher accuracy. It boosts team productivity and reduces delivery costs.Air Quality Software User Interface "Air Quality Software has set a new standard," said Brendan McCormack, Founder of Air Quality Solutions. "Air Quality Assessments are now faster, easier, and more reliable than ever before. This software reflects years of hard work and we are excited to bring it to market. " Air Quality Solutions unveils exactly how Air Quality Software has transformed air quality assessments for planning: 1. More accurate methods Traditionally, air quality consultants manually measure or estimate critical data points such as vehic
Conga Hosts Premier European Customer Conference "Conga Connection EMEA 2025" in Paris18.9.2025 10:00:00 CEST | Press release
Leading B2B SaaS Company to Host More Than 150 Customers and Partners at Flagship EMEA Event October 8 LONDON, UK / ACCESS Newswire / September 18, 2025 / Conga, the market leader in AI-powered innovation in configure, price, quote (CPQ) and contract lifecycle management (CLM), and Document Automation, will host its flagship European customer conference, Conga Connection EMEA 2025, taking place October 8, at the prestigious Pullman Paris Tour Eiffel. The event is expected to attract more than 150 customers, partners, and industry leaders from across Europe for a day of learning, innovation, and networking focused on advancing business transformation and operational excellence. The conference will feature keynote presentations from Conga's executive leadership, including CEO Dave Osborne who will share Conga's strategic vision for empowering organizations to accelerate their journey to become a more connected, intelligent business, better able to minimize risk and maximize revenue. Cong
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom